GlassScriptPhysician profile
Christopher Robert Adam
NPI 1962821355
$6,085.76
in general payments reported to CMS, 2019-2025
27 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $317 · 2021: $809 · 2022: $738 · 2023: $965 · 2024: $1,166 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.07 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,027.09 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $858.42 | 2020-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $700.38 | 2020-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $500.00 | 2019 | |
| Ani Pharmaceuticals, INC. | $378.94 | 2024-2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Biotissue Holdings INC. | $319.73 | 2022-2024 | |
| Allergan, INC. | $291.88 | 2019-2021 | |
| Abbvie INC. | $290.03 | 2022-2025 | Ozurdex |
| Astellas Pharma US INC | $286.19 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $244.85 | 2023-2025 | Syfovre |
| Eyepoint US, INC. | $164.69 | 2020-2023 | |
| Alimera Sciences, INC. | $153.93 | 2020-2024 | Iluvien, Yutiq |
| Horizon Therapeutics Plc | $151.48 | 2020-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $128.57 | 2019-2021 | |
| Oyster Point Pharma, INC. | $83.53 | 2023-2024 | Tyrvaya, Ryzumvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $82.04 | 2023-2025 | Miebo, Xipere, Vyzulta |
| Alcon Vision LLC | $70.70 | 2022-2024 | Simbrinza, Eysuvis |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $57.15 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $48.37 | 2021-2022 | |
| Harrow Eye, LLC | $46.77 | 2025 | Iheezo, Vevye |
| Amgen INC. | $32.32 | 2024-2025 | Tepezza |
| Dompe US, INC. | $30.45 | 2025 | Oxervate |
| Sight Sciences, INC. | $22.84 | 2022 | |
| Aerie Pharmaceuticals, INC. | $16.65 | 2020 | |
| Biogen, INC. | $14.65 | 2023 | |
| Sun Pharmaceutical Industries INC. | $14.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Adam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.